Asia accelerates AstraZeneca COVID-19 vaccine rollouts, as trust plunges in Europe
Many Asian countries are accelerating the rollout of AstraZeneca’s COVID-19 vaccine after confidence in its safety was hit, following reports that the shot was linked to rare blood clots in Europe earlier this month.
After briefly halting its use, many European countries have resumed using the shot in their inoculation programs after a regional regulator said it was safe, while several country leaders are also taking the vaccine to boost confidence.
For more coronavirus news, visit our dedicated page.
The AstraZeneca shot was among the first and cheapest of the COVID-19 vaccines to be developed and launched at volume and is set to be the mainstay of vaccination programs in much of the developing world.
But its brief suspension raised concerns that a slowdown in vaccination rollouts could hurt the global fight against the pandemic, as coronavirus cases surge in some countries, overwhelming healthcare systems and hurting economies.
“I have just finished getting the (AstraZeneca) injection, there is no pain at the injection site, and there is no soreness of the body,” Taiwan Premier Su Tseng-chang told reporters as the island launched its inoculation campaign on Monday.
Thailand’s prime minister also became the first person in the country to be inoculated with the AstraZeneca vaccine after its rollout was temporarily put on hold over safety concerns, while Indonesia began using it on Monday after suspending it last week. But Indonesia’s Food and Drug agency has warned against its use on people with blood clotting disorders.
South Korean President Moon Jae-in, 68, plans to get the shot on Tuesday after the government said it could be used on older people.
British Prime Minister Boris Johnson received his first dose of the AstraZeneca COVID-19 vaccine on Friday, saying he “did not feel a thing.”
The European Medicines Agency regulator said on Thursday the vaccine is effective and not linked with a rise in the overall risk of blood clots.
Yet a survey released on Monday showed that people in seven European countries were more likely to see the vaccine as unsafe than as safe.
Many Asian countries heavily rely on the AstraZeneca vaccine to end the pandemic, as the shot is being used in inoculation programs in Australia, South Korea, the Philippines, Vietnam, Thailand, and India.
Some countries could face supply issues.
India, which has the highest coronavirus caseload after the US and Brazil, is delaying supplies of the vaccine to several countries, as it faces a second surge in cases, said a source with direct knowledge of the matter.
For all the latest headlines follow our Google News channel online or via the app.
The Serum Institute of India (SII), which produces the AstraZeneca vaccine, has told Brazil, Saudi Arabia and Morocco that further supplies will be delayed due to surging demand at home, the person said.
Australia, which has inoculated just 1 percent of its population so far, is also accelerating vaccination after the country’s pharmaceutical regulator approved on Sunday the local manufacturing of the AstraZeneca vaccine by CSL.
Within 12 weeks, CSL is expected to produce 1 million doses of the vaccine each week.
A year on from lockdown, India reports worst daily rise in COVID-19 in months
India’s Serum Institute delays vaccine shipments to Brazil, Morocco, Saudi
WHO gives nod to AstraZeneca vaccine and its ‘tremendous potential’
WHO gives nod to AstraZeneca vaccine and its ‘tremendous potential’The World Health Organization’s vaccine safety panel said on Friday that available data from AstraZeneca’s COVID-19 shot do not point to any overall ... Coronavirus
Indonesia resumes use of AstraZeneca vaccine, following Europe’s leadIndonesia on Friday cleared the AstraZeneca vaccine for use again after the European Union’s drug regulator said the vaccine didn’t increase the ... Coronavirus
Nearly a dozen countries resume AstraZeneca COVID-19 vaccinesNearly a dozen countries resumed use of AstraZeneca’s COVID-19 shots on Friday as EU and British regulators said the benefits outweighed any risks ... Coronavirus